Biontech and autolus announce strategic car-t cell therapy collaboration to advance pipeline and expand late-stage programs

Mainz, germany and london, united kingdom, february 8, 2024 –  biontech se  (nasdaq: bntx, “biontech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and autolus therapeutics plc  (nasdaq: autl, “autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announced a strategic collaboration aimed at advancing both companies' autologous car-t programs towards commercialization, pending regulatory authorizations. in connection with the strategic collaboration, the companies entered into a license and option agreement and a securities purchase agreement.
BNTX Ratings Summary
BNTX Quant Ranking